

HUMAN PERIOSTIN/OSF-2 ELISA KIT

FOR THE QUANTITATIVE DETERMINATION OF
HUMAN PERIOSTIN/OSF-2 CONCENTRATIONS
IN SERUM AND EDTA PLASMA



FOR RESEARCH USE ONLY. NOT FOR USE IN
DIAGNOSTIC PROCEDURES.

PURCHASE INFORMATION:

ELISA NAME	HUMAN PERIOSTIN/OSF-2 ELISA
Catalog No.	SK00072-08
Lot No.	
Formulation	96 T
Standard range	7.8-500 ng/ml
Sensitivity	3.9 ng/ml
Sample require	100 µl
Dilution Factor	<i>Optimal dilutions should be determined by each laboratory for each application</i>
Sample Type	Serum, EDTA Plasma
Specificity	Human Periostin/OSF-2
Intra-assay Precision	4-6%
Inter-assay Precision	8-12%
Storage	2-8 °C

ORDER CONTACT:

AVISCERA BIOSCIENCE, INC
2348 Walsh Ave., Suite C
Santa Clara, CA 95051
USA
Tel: (408) 982 0300
Email: Sales@AvisceraBioscience.com
Website: www.AvisceraBioscience.com

INTRODUCTION

Human Periostin immunoassay is a 3.5 - 4.5 hour solid phase ELISA designed to measure human Periostin in serum and plasma. It contains recombinant human Periostin and antibodies raised against this protein. It has been shown to accurately quantify recombinant human Periostin. Results obtained with naturally occurring Periostin samples showed linear curves that were parallel to the standard curves obtained using the kit standards. These results indicate that the immunoassay kit can be used to determine relative mass values for natural human Periostin.

PRINCIPLE OF THE ASSAY

This assay employs the quantitative sandwich enzyme immunoassay technique. A polyclonal antibody specific for Periostin has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any Periostin present is bound by the immobilized antibody. After washing away any unbound substances, a biotinylated polyclonal antibody specific for Periostin is added to the wells. Following a wash to remove any unbound antibody reagent, a streptavidin-HRP conjugate is added to the wells. After washing away any unbound enzyme, a substrate solution is added to the wells and color develops in proportion to the amount of Periostin bound in the initial step. The color development is stopped and the intensity of the color is measured.

LIMITATIONS OF THE PROCEDURE

_ FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.

_ The kit should not be used beyond the expiration date on the kit label.

_ Do not mix or substitute reagents with those from other lots or sources.

_ It is important that the Dilution Buffer selected for the standard curve be consistent with the samples being assayed.

_ If samples generate values higher than the highest standard, dilute the samples with Dilution Buffer and repeat the assay.

_ Any variation in dilution buffer, operator, pipetting technique, washing technique, incubation time or temperature, and kit age can cause variation in binding.

_ This assay is designed to eliminate interference by soluble receptors, binding proteins, and other factors present in biological samples. Until all factors

have been tested in the immunoassay, the possibility of interference cannot be excluded.

MATERIALS PROVIDED

DESCRIPTION	CODE	QUANTITY
Periostin Microplate - 96 well polystyrene microplate (12 strips of 8 wells) coated with a purified polyclonal IgG against Periostin.	072-08-01	1 plate
PERIOSTIN Standard – 500 ng/vial of recombinant human Periostin in a buffered protein base with preservatives; lyophilized.	072-08-02	1 vial
Detection Antibody – 105 µL/vial, 100-fold concentrated of a purified polyclonal IgG against PERIOSTIN with preservatives; lyophilized.	072-08-03	1 vial
Positive Control – one vial of recombinant Periostin, lyophilized	072-08-04	1 vial
Streptavidin HRP Conjugate - 60 µl/vial, 200-fold concentrated solution of Streptavidin HRP conjugate	SAHRP	1 vial
Dilution Buffer - 60mL of buffered protein based solution with preservatives	DB06	1 bottle
HRP Diluent Solution - 12mL of buffered protein based solution with preservatives	DB01	1 bottle
Wash Buffer - 50 mL of 10-fold concentrated buffered surfactant, with preservative.	WB01	1 bottle
TMB Substrate Solution - 11 mL of TMB substrate solution	TMB01	1 bottle
Stop Solution - 11 mL of 0.5M HCl	S-STOP	1 bottle
Plate Sealer	EAPS	1 piece
Plastic Pouch	P01	1 piece

STORAGE

Unopened Kit: Store at 2 - 8° C for up to 12 months. For longer storage, unopened Standard, Positive Control and Detection Antibody Concentrate should be stored at -20 or -70°C. Do not use kit past expiration date.

Opened / Reconstituted Reagents: Reconstituted Standard and Antibody Solution SHOULD BE STORED at -20 °C or -70°C for up to one month. Streptavidin-HRP Conjugate 200-fold concentrated and other components may be stored at 2 - 8°C for up to 12 months.

Microplate Wells: Return unused wells to the plastic pouch with the desiccant pack, reseal along entire edge of zip-seal. Microplate may be stored for up to 6 months at 2 - 8° C after opening.

OTHER SUPPLIES REQUIRED

- Microplate reader capable of measuring absorbance at 450 nm, with the correction wavelength set at 540 nm or 570 nm.
- Microplate shaker (250-300rpm).
- Pipettes and pipette tips.
- Deionized or distilled water.
- Squirt bottle, manifold dispenser, or automated microplate washer.
- 100 mL and 500 mL graduated cylinders.

PRECAUTIONS FOR USE

All reagents should be considered as potentially hazardous. The stop solution contains diluted hydrochloric acid. Appropriate care, therefore, should be taken while handling this solution. We therefore recommend that this product is handled only by those persons who have been trained in laboratory techniques and that it is used in accordance with the principles of good laboratory practice. Wear suitable protective clothing such as laboratory overalls, safety glasses and gloves. Care should be taken to avoid contact with skin or eyes. In the case of contact with skin or eyes wash immediately with water.

SAMPLE COLLECTION AND STORAGE

Serum - Use a serum separator tube (SST) and allow samples to clot for 30 minutes before centrifugation for 15 minutes at 1000 x g. Remove serum and assay immediately or aliquot and store samples at ≤ -20° C. Avoid repeated freeze-thaw cycles.

Plasma - Collect plasma using EDTA, heparin, or citrate as an anticoagulant. Centrifuge for 15 minutes at 1000 x g within 30 minutes of collection. Assay immediately or aliquot and store samples at ≤ -20° C. Avoid repeated freeze-thaw cycles.

Note: Use Aprotinin (enzyme inhibitor) (Code No.: 00700-01-25) for ALL sample collection to prevent

sample degradation. 0.5 TIU per ml of sample solution.

SAMPLE PREPARATION

Serum and plasma samples may need to be diluted. A pretest will help determine the optimal dilution factor for the samples. **Optimal dilutions should be determined by each laboratory for each application. Use polypropylene test tubes.**


REAGENT PREPARATION

Bring all reagents to room temperature before use.

Wash Buffer - If crystals have formed in the concentrate, warm to room temperature and mix gently until the crystals have completely dissolved. Dilute 50 mL of Wash Buffer Concentrate into deionized or distilled water (450 mL) to prepare 500 mL of Wash Buffer.

Periostin Standard - Refer to vial label for reconstitution volume. Reconstitute the Periostin standard with 1.0 ml of Dilution Buffer. This reconstitution produces a stock solution of 500 ng/mL. Allow the standard to sit for a minimum of 15 minutes with gentle agitation prior to making dilutions. Pipette 250 µL of Dilution Buffer into tubes #1 to #6. Use the stock solution to produce a dilution series (below). Mix each tube thoroughly before the next transfer. The 500 ng/mL standard serves as the high standard. The Dilution Buffer serves as the zero standard (0 ng/mL).

TUBE	STANDARD	DILUTION BUFFER	CONCENTRATION
stock	powder	1 ml	500 ng/ml
# 1	250µl of stock	250µl	250 ng/ml
# 2	250µl of 1	250µl	125 ng/ml
# 3	250µl of 2	250µl	62.5 ng/ml
# 4	250µl of 3	250µl	31.25 ng/ml
# 5	250µl of 4	250µl	15.6 ng/ml
# 6	250µl of 5	250µl	7.8 ng/ml



Concentration 500 250 125 62.5 31.2 15.6 7.8 ng/ml

Detection Antibody Concentrate - Reconstitute the Detection Antibody Concentrate with 105 µL of Dilution Buffer to produce a 100-fold concentrated stock solution. Pipette 10.395 mL of Dilution Buffer into a 15 mL centrifuge tube and transfer 105 µL of 100-fold concentrated stock solution to prepare working solution.

Streptavidin-HRP Conjugate - Transfer 60 µL of 200-fold concentrated Streptavidin-HRP conjugate stock solution to 11.94 mL of **HRP Diluent Solution (DB01)** to prepare working solution. **Note:** 1x working solution of Streptavidin-HRP Conjugate should be used within a few days.

Positive Control - Reconstitute the Positive Control with 1.0 mL of Dilution Buffer. **Note:** Positive Control should be prepared and used immediately. Reconstituted Positive Control CAN NOT BE REUSED.


ASSAY PROCEDURE

Bring all reagents and samples to room temperature before use. It is recommended that blank, standards, sample and positive control be assayed in duplicates.

1. Prepare all reagents and working standards as directed in the previous sections.
2. Remove excess micro-plate strips from the plate frame, return them to the plastic pouch with the desiccant pack, reseal.
3. Add 100 µL of Dilution Buffer to Blank well (B2, B3).
4. Add 100 µL of Standard solution from #6 to S (reverse order of serial dilution) (from C2, C3 to F2, F3 and F4, F5 to D4, D5), sample, or positive control (C4, C5) per well. Cover with plate sealer. Incubate for 2 hours on micro-plate shaker at room temperature. A plate layout is provided to record standards and samples assayed.
5. Aspirate each well and wash, repeating the process three times for a total of four washes. Wash by filling each well with 1x Wash Buffer (300 µL) using a squirt bottle, manifold dispenser, or autowasher. Complete removal of liquid at each step is essential to good performance. After the last wash, remove any remaining Wash Buffer by aspirating or decanting. Invert the plate and blot it against clean paper towels.
6. Add 100 µL of Detection Antibody working solution to each well. Cover with sealer. Incubate

for 2 hours on micro-plate shaker at room temperature.

7. Repeat the aspiration/wash as in step 5.
8. Add 100 µL of Streptavidin-HRP Conjugate working solution to each well. Incubate for 60 minutes on micro-plate shaker at room temperature. **Protect from light.**
9. Repeat the aspiration/wash as in step 5.
10. Add 100 µL of Substrate Solution to each well. Incubate for 10-15 minutes at room temperature. **Protect from light.**
11. Add 100 µL of Stop Solution to each well. The color in the wells should change from blue to yellow. If the color in the wells is green, or if the color change does not appear uniform, gently tap the plate to ensure thorough mixing.
12. Determine the optical density of each well within 15 minutes, using a micro-plate reader set to 450 nm. If wavelength correction is available, set to 540 nm or 570 nm. If wavelength correction is not available, subtract readings at 540 nm or 570 nm from the readings at 450 nm. This subtraction will correct for optical imperfections in the plate. Readings made directly at 450 nm without correction may be higher and less accurate.



CALCULATION OF RESULTS

Average the duplicate readings for each standard, positive control, and sample and subtract the average zero standard optical density. Create a standard curve by reducing the data using computer software capable of generating a log-log curve fit. As an alternative, construct a standard curve by plotting the mean absorbance for each standard on the y-axis against the concentration on the x-axis and draw a best fit curve through the points on the graph. The data may be linearized by plotting the log of the Periostin concentrations versus the log of the O.D.

and the best fit line can be determined by regression analysis. This procedure will produce an adequate but less precise fit of the data.

If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.

Calculation of samples with a concentration exceeding that of standard 500 ng/ml may result in inaccurate, low human Periostin levels. Such samples require further external predilution according to expected human Periostin values with Dilution Buffer in order to precisely quantify the actual human Periostin level.

CALIBRATION

This immunoassay is calibrated against a highly purified recombinant human Periostin/OSF-2.

SENSITIVITY

Twenty-five assays were evaluated and the minimum detectable dose (MDD) of Periostin was 3.9 ng/mL.

SPECIFICITY

PROTEIN	CROSS-REACTIVITY
Human Periostin	100%
Human Osteoponin	0
Human OSF-1/PTN	0
Human Osteoprotegerin	0
Human RAGE, ECD	0
HFABP	0

TYPICAL DATA

This standard curve data is provided for demonstration only. A standard curve should be generated for each set of samples assayed.

STANDARD (NG/ML)	AVERAGE OD450 (CORRECTED)
Blank	0 (0.139)
7.8	0.038
15.6	0.069
31.25	0.116
62.5	0.192
125	0.363
250	0.668
500	1.422

LINEARITY

To assess the linearity of the assay, commercially bought pooled serum samples were diluted with Dilution Buffer (DB06) and assayed.

DILUTION FACTOR	ASSAYED (NG/ML)	FINAL (NG/ML)	RECOVERY (%)
40X	539.863	21594.52	100
80X	290.029	23202.32	107

To assess the linearity of the assay, commercially bought pooled EDTA plasma samples were diluted with Dilution Buffer (DB06) and assayed.

DILUTION FACTOR	ASSAYED (NG/ML)	FINAL (NG/ML)	RECOVERY (%)
40X	213.471	8538.84	100
80X	115.369	9229.52	108

REFERENCES

1: Zhu M, et al. Periostin promotes ovarian cancer angiogenesis and metastasis. *Gynecol Oncol.* 2010 Nov;119(2):337-44. Epub 2010 Aug 4.

2: Sidhu SS, et al. Roles of epithelial cell-derived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma. *Proc Natl Acad Sci U S A.* 2010 Aug 10;107(32):14170-5. Epub 2010 Jul 26.

3: Fortunati D, et al. Periostin is a collagen associated bone matrix protein regulated by parathyroid hormone. *Matrix Biol.* 2010 Sep;29(7):594-601. Epub 2010 Jul 21.

4: Takada M, . Periostin, discovered by nano-flow liquid chromatography and mass spectrometry, is a novel marker of diabetic retinopathy. *Biochem Biophys Res Commun.* 2010 Aug 20;399(2):221-6. Epub 2010 Jul 21.

5: Hakuno D, et al. Periostin advances atherosclerotic and rheumatic cardiac valve degeneration by inducing angiogenesis and MMP production in humans and rodents. *J Clin Invest.* 2010 Jul 1;120(7):2292-306. doi: 10.1172/JCI40973. Epub 2010 Jun 14.

6: Tischler V, et al. Periostin is up-regulated in high grade and high stage prostate cancer. *BMC Cancer.* 2010 Jun 9;10:273.

7: Michaylira CZ, et al. Periostin, a cell adhesion molecule, facilitates invasion in the tumor microenvironment and annotates a novel tumor-invasive signature in esophageal cancer. *Cancer Res.* 2010 Jul 1;70(13):5281-92. Epub 2010 Jun 1. Erratum in: *Cancer Res.* 2010 Aug 1;70(15):6398.

SUMMARY OF ASSAY PROCEDURE

PREPARE REAGENTS, SAMPLES AND STANDARDS
↓
Add 100 µl of standard, samples, positive control to each well. Incubate 2 hours on the plate shaker at RT.
↓
Aspirate and wash 4 times.
↓
Add 100 µl Detection Antibody working solution to each well. Incubate 2 hours on the plate shaker at RT.
↓
Aspirate and wash 4 times.
↓
Add 100 µl Streptavidin-HRP conjugate working solution to each well. Incubate 1 hour on the plate shaker at RT. Protect from light.
↓
Aspirate and wash 4 times.
↓
Add 100 µl Substrate solution to each well. Incubate 10-15 min on plate shaker. Protect from light.
↓
Add 100 µl Stop Solution to each well. Read 450nm within 15 min